µMT-/- recipient mice Incidence Onset Peak CDI Mortality
no cells Ctrl 6/6 12.2±0.2 5.0±0.0 64.8±1.4 1
no cells E2 7/7 17.1±0.8a 4.5±0.4 40.9±4.6a 1
+ PD-L1-/- B cells Ctrl 8/8 9.8±0.3 4.8±0.2 64.9±1.9 0
+ PD-L1-/- B cells E2 8/8 17.3±0.6a 4.2±0.2a 32.6±2.2a 0
+ PD-L2-/- B cells Ctrl 10/10 11.8±0.5 5.0±0.0 63.9±2.8 0
+ PD-L2-/- B cells E2 6/11 22.8±0.7a,b,c 3.6±0.7a 6.8±2.7a,b,c 0
asignificant (p ≤ 0.05) as compared to respective Ctrl group
bsignificant (p ≤ 0.05) as compared to E2-implanted PD-L1-/- B cell-recipient group
csignificant (p ≤ 0.05) as compared to E2-implanted no cell transfer μMT-/- recipient group
*Statistical evaluation of EAE disease course for Control and E2-implanted recipient μMT-/- mice, including the Cumulative Disease Index (CDI), through day 26 postimmunization for the 2-3 experiments (n=3-5 mice/group/experiment). The daily disease scores from pooled data and corresponding CDI data from each of the independent experiments (mean ± SEM) are presented. Additional information for the experiments is shown in Figure 6.
Table 2: Clinical course of EAE in B-cell-recipient μMT-/- mice*.